Abstract: Pembrolizumab is a full-length human immunoglobulin G4 (IgG4) monoclonal antibody directed against the immune checkpoint PD-1 to remove its binding with PD-L1 and thus to restore an anti-tumor immune response of T cells. Pembrolizumab is one of the most advanced immune checkpoint inhibitors for cancer care. Apart from rare and serious adverse effects, its favorable tolerance profile enables to treat fragile patients who have often no other choice than best supportive care. The effective retained dose of pembrolizumab is a venous administration of 200 mg every 3 weeks until disease progression, intolerance or up to 24 months. Pembrolizumab has already proven its efficacy and thus obtained marketing authorization in so-called hot or hypermutated tumors or tumors expressing PD-L1 such as melanomas, non-small cell lung cancers, urothelial carcinomas, cervical cancer, etc. Pembrolizumab is also authorized in the United States in the treatment of mismatch repairdeficient tumors or with microsatellite instability. The current challenge is to expand its use in tumor types that are supposed to be less immunogenic, for example, by attempting to warm up the tumor microenvironment, or by combining pembrolizumab with other molecules. An acceptable toxicity profile of such combinations remains to explore. We review here the current indications of this drug, the main prognostic and predictive factors of its efficacy as well as the potential forthcoming indications.
Introduction
Immunotherapy is a major breakthrough of cancer therapy in recent years, as shown by the awarding of the 2018 Nobel Prize in Medicine to immunologist James Allison. To restore the patient's own anti-tumor immunity is now a successful strategy in opposition to conventional cytotoxic or targeted therapy. Pembrolizumab is a major weapon in the immunotherapy pipeline, and we review here the latest data on its development.
PD-L1 expression as predictive biomarker. A pooled analysis of 14 trials has shown an overall response rate (ORR) of 26% with this drug (95% Confidence Interest (CI) 21 to 31). 8 
d. Tolerance of pembrolizumab
The safety profile is satisfactory and superimposable with other checkpoint inhibitors. Overall, the incidence of any grade treatment adverse events (AE) in 3922 patients was 74 .3% (95% CI 0.671 to 0.805). 9 A meta-analysis of 11 studies found 9% (95% CI 6% to 14%) of grade 3/4 AE, 8 significantly lower than conventional treatments. Overall, 5% of the patients went out of clinical trial for unacceptable toxicity. The most common AE are fatigue, diarrhea, nausea, rash and pruritus, myalgia and arthralgia. Less frequent but more concerning AE are the so-called immune-related Adverse Events (irAEs) related to the therapeutic class of pembrolizumab and generally consistent across tumor types. 10 Endocrine irAES are the most frequent, with 10-15% of hypothyroidism/hyperthyroidism and 1-3% of hypophysitis (1-3%). 11, 12 Some rare but life-threatening AE have been reported with like encephalopathy, 13 pneumonitis, 14 nephritis, 15 hepatitis, 16 myocarditis, 17 and colitis. 18 Their management includes the suspension of the drug, substitutive opotherapy and immunosuppression by high doses of corticosteroids or powerful immunosuppressant like tumor necrosis factor antagonists or mycophenolate mofetil. 2. Approved indications for pembrolizumab a. Melanoma Table 1 summarize current approved indications for pembrolizumab. In 2015, pembrolizumab monotherapy was the first anti-PD1 antibody approved in Europe for treating advanced melanoma progressing on standard therapy based on data from KEYNOTE-001 and KEYNOTE-002. 19, 20 The KEYNOTE-006 comparing pembrolizumab to ipilimumab in first or second line leads to an extension of this approval for previously untreated melanoma regardless of BRAF status. 21 This trial showed an impressive overall survival (OS) benefit for pembrolizumab: 32.7 vs 15.9 months (HR 0.73 (95%CI 0.61 to 0.89)). Among the 103 patients who continued 2 years of pembrolizumab, 86% were free of progression 20 months after discontinuation of the drug. Recently, the FDA has accepted a supplemental biologics license application (sBLA) for the use of pembrolizumab as an adjuvant treatment for patients with high-risk resected stage III melanoma, based on the KEYNOTE-054 trial. 36 Hazard ratio for recurrence or death was 0.57 (98.4% CI, 0.43 to 0.74), P<0.001.
b. Lung cancer NSCLC
Following KEYNOTE-010, 22 pembrolizumab was approved in 2015 in second line for PD-L1-positive (Tumor proportion score (TPS) ≥1%) NSCLC pretreated by chemotherapy or tyrosine kinase inhibitor (TKI) if epidermal growth factor receptor (EGFR) mutated or anaplastic lymphoma kinase (ALK)-rearranged. Based on KEYNOTE-024 trial, 23 indication was extended in 2016 to front line EGFR/ALK wild type PD-L1+ (TPS≥50%) NSCLC. Of note, the KEYNOTE-042, 37, 24 in the same context but with a different PD-L1 expression (TPS score ≥1%), did not show any benefit of pembrolizumab vs chemotherapy in that broader population. More recently, a combination with pemetrexed and platinum chemotherapy as first line has been approved based on an OS improvement in the KEYNOTE-189 trial. 25 OS benefit was seen across all PD-L1 categories of PD-L1 expression.
Squamous cell NSCLC
Pembrolizumab plus carboplatin/paclitaxel or nabpaclitaxel should become a new standard of care for the first-line treatment base on significant OS benefit in the KEYNOTE-407. 26 Interestingly, the grade 3 AE was lower in the combination arm (74.5% vs 64.4%). Pembrolizumab benefit was independent from PD-L1 TPS expression, but the magnitude of the benefit was correlated with PD-L1 expression.
c. Bladder cancer
The KEYNOTE-045 leads to the FDA approval of pembrolizumab for urothelial carcinoma progressing after platinum comparing pembrolizumab with investigator's choice chemotherapy in second-line. 27 Interestingly the Results showed an ORR of 13.3% with responses restricted to PD-L1+ tumors.
e. Gastrointestinal cancers Gastric cancer
The KEYNOTE-059 phase II trial included advanced gastric cancer (≥2 lines). 31 ORR was 11.6%. ORR was 15.5% and 6.4% for PD-L1-positive and negative patients, respectively. Given the benefit in RR and DOR, the FDA has granted marketing authorization for patients with PD-L1+ gastric cancer on the 3rd or higher line. 40 The phase III KEYNOTE-061 failed to confirm the superiority of pembrolizumab to paclitaxel chemotherapy as a second-line therapy with post-hoc interesting results in MSI high tumors. 32 The ongoing phase III trial KEYNOTE-062 is testing the frontline combination of pembrolizumab + Cisplatinum/5FU in PD-L1+ and HER2 negative tumors. 
f. Head and neck
The FDA approved pembrolizumab for recurrent or metastatic HNSCC on August 5, 2016. 42 The KEYNOTE-012 is the first study investigating a PD-1 antibody for recurrent or metastatic HNSCC who progressed after platinum-containing chemotherapy. [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] ORR was 18% including 4% of CR and a ≥6 months DOR in 85% of the patients. The randomized phase III trial KEYNOTE-048 evaluated pembrolizumab monotherapy or combined with platinum/5FU chemotherapy vs the EXTREME regimen as first-line fin 882 PD-L1 CPS≥20% HNSCC. 45 Pembrolizumab alone or with chemotherapy significantly improved OS supporting pembrolizumab or pembrolizumab + platinum/5-FU as a new first-line standards of care for recurrent or metastatic HNSCC.
g. MSI-H or dMMR tumors
Five similar trials included 149 patients with various tumor types characterized by microsatellite instability-high (MSI-H) high or mismatch repair deficient (dMMR) (KEYNOTE-016 (n=58), KEYNOTE-164 (n=61), KEYNOTE-012 (n=6), KEYNOTE-028 (n=5), and KEYNOTE-158 (n=19)). The ORR with pembrolizumab across studies was 39.6% with 78% of responses lasting ≥6 months. These innovative data led to an FDA granted accelerated approval for pembrolizumab in MSI-H or dMMR solid tumors progressing on treatment and without satisfactory alternative treatment options. This is the first time that a drug has a tissue-agnostic market authorization.
Promising therapeutic trials of pembrolizumab
Here are detailed the most promising trials of pembrolizumab as a monotherapy ( In the KEYNOTE-158, a phase II basket study, 49 out of the 107 SCC, RR was 35.7% in PD-L1+ tumors vs 6.0% in PD-L1-tumors. The KEYNOTE-604 randomizes pembrolizumab/placebo with chemotherapy for newly diagnosed advanced SCC. 50 Maintenance therapy with pembrolizumab was evaluated in 45 patients with advanced SCC following 4-6 cycles of platinum/etoposide. 51 The disease control rate was 42% (1 CR, 3 PR, and 15 SD) and median PFS and OS were 1.4 months and 9.2 months, respectively. In this small cohort, pembrolizumab did not improve PFS but improved OS suggesting that some patients might benefit from this strategy.
Malignant pleural mesothelioma (MPM)
PD-L1 is expressed in 20-40% and is a factor of worse prognosis.
52,53
Pembrolizumab monotherapy provide a 20% ORR in PDL1+ TPS≥1% MPM. 54 
Prostate cancer
The KEYNOTE-199 trial is a 5-cohort phase II trial studying pembrolizumab monotherapy in metastatic pretreated CRPC. 60 Anti-tumor activity was observed in all cohorts: disease control rate (DCR) was 26% (95% CI 21 to 32) with 11% of the patients presenting DCR lasting more than 6 months.
c. Breast cancer Neoadjuvant setting
Pembrolizumab combined with chemotherapy provided up to 80% pathological response (ypT0 ypN0) in triple negative breast cancer (TNBC) in the KEYNOTE-173 trial.
61
The I-SPY2 phase II study assessed the addition of pembrolizumab to neoadjuvant paclitaxel followed by doxorubicin + cyclophosphamide for ≥T2 HER2 negative BC. 62 Pembrolizumab improved pCR rates in all HER2 subtypes (pCR rate 46% vs 16%), especially in TNBC. The KEYNOTE-522 is currently evaluating pembrolizumab + neoadjuvant chemotherapy followed by adjuvant pembrolizumab in TNBC. 
TNBC
Atezolizumab, an anti-PD-L1 antibody has shown a very interesting PFS benefit in front line therapy for TNBC in combination with nab-paclitaxel. 64 The Keynote-355 has randomized pembrolizumab/placebo with various regiments of chemotherapy (nab-paclitaxel, paclitaxel, or carboplatin/gemcitabine) in the same setting. 65 The principal objectives are PFS and OS in all patients and in patients with PD-L1-positive tumors defined as PD-L1 staining in ≥1% tumor cells or in stroma. The results are warmly awaited in the next 6 months.
HER2 positive BC
The PANACEA Study evaluated pembrolizumab in combination with trastuzumab in patients with trastuzumabresistant, HER2+, PD-L1-positive (phase Ib) or negative (phase II) metastatic breast cancer. 66 For PD-L1+ patients (n=40) ORR and DCR were 15% and 25%, respectively. No objective responses were observed in the PD-L1 negative cohort (n=12).
d. Gynecological cancer Endometrial cancer
POLE (polymerase Ɛ) mutated (6-12%) and MSI endometrial tumors exhibited significantly elevated TILs, high expression of PD-1 and PD-L1 and greater peritumoral T-lymphocytes supporting trials of immune-checkpoint inhibitors. 67, 68 An ongoing single-institution phase II study of pembrolizumab in MMR deficient cancers included 9 patients with endometrioid carcinoma and showed an ORR of 56%, including 1 CR. 69 The KEYNOTE-775 is currently evaluating pembrolizumab plus lenvatinib vs chemotherapy in second line endometrial cancer (NCT03517449).
Ovarian cancer
KEYNOTE-100 is an ongoing phase II for relapsing ovarian cancer after front-line platinum-based therapy. 70 Of the 376 patients included, ORR was 9%, median PFS was 2.1 months. ORR reaches 14% and 25% for patients with PD-L1 CPS ≥1% and ≥10%. Homologous recombination deficiencies are a frequent hallmark of serous high-grade ovarian cancer leading to the approval of PARP inhibitors. 
Esophageal cancer
The phase II KEYNOTE-180 will evaluate pembrolizumab as a monotherapy in patients with previously treated advanced or metastatic esophageal cancer. 76 KEYNOTE-181 is a phase III trial comparing pembrolizumab vs standard therapy in advanced esophageal or gastroesophageal junction carcinoma that progressed after firstline therapy. 77 KEYNOTE-590 is designed to evaluate efficacy and safety of pembrolizumab vs placebo plus cisplatin and 5-FU chemotherapy as first-line treatment in participants with locally advanced or metastatic esophageal carcinoma.
Squamous cell carcinoma of the anal canal (SCCA)
KEYNOTE-028 included PD-L1+ SCCA. PD-L1 positivity was found in 74% of the screened patients. Among the 24 patients, no CR were noted but 4 patients had a PR, for an ORR of 17%, and 10 patients (42%) had a confirmed stable disease. The DCR was 58%. 78 A phase II study in refractory metastatic SCCA is currently recruiting (NCT02919969).
Biliary tract
PD-L1 is highly expressed in cholangiocarcinoma in association to a high density of CD3-positive tumor-infiltrating lymphocytes suggesting a potential role for pembrolizumab. 79 KEYNOTE-028 basket trial enrolled 24 patients with PD-L1+ biliary tract cancer to receive pembrolizumab monotherapy. 80 Four PR have been DovePress observed prompting a successor biliary cancer cohort of 100 patients in the ongoing KEYNOTE-158 basket trial (NCT02628067). Not yet recruiting, the NCT03260712 will evaluate Cisplatin + Gemcitabine and pembrolizumab in that context.
f. Head and neck
The KEYNOTE-055 phase II study included 171 patients with HNSCC progressing within 6 months of platinum-based chemotherapy with cetuximab. 81 82% of the patients were PD-L1 positive and 22% were HPV positive. ORR with pembrolizumab monotherapy was 16% with a median DOR of 8 months (range: 2 to 12). Response rates were similar in all HPV and PD-L1 subgroups. Median PFS and OS were 2.1 and 8 months, respectively. The KEYNOTE-040 was a randomized phase III study which included patients with HNSCC after a platinumbased chemotherapy to receive either pembrolizumab or standard of care. 35 Primary endpoint (PFS and OS) was not reached. Median OS was not statistically higher with pembrolizumab. Subgroups analyses showed a weighty prolonged OS proportionally to PD-L1 expression: OS was 8.7 months (HR=0.75 (95% CI 0.59 to 0.95), P=0.0078) for PD-L1 CPS≥1%; and OS was 11.6 vs 7.9 months (HR=0.54 (95% CI 0.35 to 0.82), P=0.0017) for PD-L1 TPS ≥50%.
The following ongoing studies will evaluate pembrolizumab for high-risk HNSCC in both neoadjuvant and adjuvant setting (phase II, NCT02641093; phase II for HPV negative HNSCC NCT02296684). 82 KEYNOTE-412 will evaluate the addition of pembrolizumab in combination with concomitant chemo-radiotherapy for locally advanced HNSCC. 83 
g. Rare tumors
ACSé pembrolizumab (NCT03012620) is a multi-cohort phase II study designed to propose secured accessed to pembrolizumab for patients with rare cancer. Seven cohorts are recruiting including rare sarcoma, rare ovarian cancer, primary central nervous system lymphomas, rare thyroid cancer, rare malignant neuroendocrine cancer, germ-cell cancer, and NK/T-cell lymphoma.
4. Predictive factors of response to pembrolizumab and selection of patients a. PD-L1 status PD-L1 expression is the main predictive biomarker of response, and its expression is often associated with a poor prognosis. Some important questions are still unsolved. Whether the PD-L1 positivity must be determined on tumor cell, immune cell or both is unknown. Therefore, PD-L1 positivity definitions vary across studies with scores like tumor proportion score (TPS) or combined proportion score (CPS) which is the sum of the percentage of PD-L1 expressing tumor cells and immune cells as a fraction of the number of tumor cells. 84 The optimal threshold of PD-L1 positivity to select the patients is not established varying from 1% to 50%, for example, in NSCLC and different antibodies are used. In addition, some variations of PD-L1 expression have been observed between the course of the disease raising the question of the best moment to evaluate PD-L1 expression (primitive tumor vs metastases). 85, 86 Lastly, complete response are observed in 17% of the PD-L1-negative advanced melanoma. 87 PD-L1 positivity is important but not sufficient for identify responders.
b. Mutational load and neoantigen burden
The tumor mutational load (TML) corresponds to the somatic mutation rate for a given tumor and varies according to the tissue of origin of cancer. 88 A high TML leads to the expression of multiple neoantigens and triggers an immune response. Therefore, a high TML is potentially associated with the efficacy of checkpoint inhibitors. These observations were validated in two cohorts of lung cancer receiving pembrolizumab where a high TML was associated with ORR, durable clinical benefit, and PFS. 89 A retrospective study of various tumor types showed that mutational load and T-cell-inflamed microenvironment were predictors of response to pembrolizumab. 90 Median number of mutations was 180 in responders vs 61 in nonresponders. Another retrospective study including various tumor types demonstrated that a threshold of ≥20 mutations/megabase was associated with improved ORR, PFS, and OS . 91 Prospective study data are expected to validate the value of TMB.
c. Mismatch repair deficiency
An analysis of tumor mutational load in 100,000 cancer genomes identified a novel mutation hotspot in the promoter of the DNA mismatch repair gene PMS2, that was significantly associated with high tumor mutational load. 92 Whole-exome sequencing also showed that MMR deficient tumors are largely most mutated than MMR proficient tumors (1782 vs 73 somatic mutations per tumors, P=0.007) associated with prolonged PFS patients demonstrated a manageable toxicity with fever, N/V, headache, hypotension, and rigors. Grade 3/4-related AEs were reported in 15 of 68 patients. The ORR across all dose cohorts on weekly (n=40) and Q3W schedules (n=13) were 22.5% (9/40; 95% CI 11% to 39%) and 7.7%% (1/13; 95% CI 0% to 36%) respectively. Distant regression of non-injected tumors occurred in cutaneous, nodal, hepatic, and splenic metastases. CMP−001 dosing at 5 mg/weekly has been selected for further evaluation in the ongoing dose expansion phase of this study. Epacadostat is an indoleamine−2,3-dioxygenase 1 (IDO1) inhibitor. IDO1 is an endogenous mechanism of acquired peripheral immune tolerance in vivo. 104 Several therapeutic trials are evaluating epacadostat with pembrolizumab. Two ongoing phase III studies are testing the combination in UC, after first-line platinum, 105 or for cisplatinum-ineligible patients106 In head and neck SCC, the phase I/II study ECHO-202/KEYNOTE-037 also have shown promising results with an ORR for patients with 1-2 or 3 prior line of 34% and 14%, respectively. 107 An ongoing phase III study randomizes pembrolizumab plus epacadostat vs pembrolizumab and vs the EXTREME regimen as first-line treatment for advanced head and neck squamous cell carcinoma (ECHO-304/KEYNOTE-669). 108 However a phase III in melanoma failed to increase PFS compared to pembrolizumab monotherapy. 109 
b. Combination with other checkpoint inhibitor
Although pembrolizumab has supplanted ipilimumab in the management of melanoma, it was the first checkpoint inhibitor to demonstrate its efficacy in melanoma. The KEYNOTE-029, 110 an open-label phase Ib study tested pembrolizumab 2 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses, followed by pembrolizumab 
Conclusion
The role of pembrolizumab in the management of cancer is no longer to prove. Indeed, many marketing authorizations have been granted to pembrolizumab by the FDA in various types of cancer. Better tolerated and more effective than conventional treatments, this makes it a treatment of choice. Selecting the patients benefiting at best from the therapy remains challenging. PD-L1 expression, the most used biomarker, remains imperfect. Numerous combination trials are ongoing.
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